The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies

Area of Science:

• Gynecologic Oncology
• Immunotherapy
• Cancer Biomarkers

Background:

• Programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have shown efficacy in various cancers.
• Their activity in gynecologic malignancies, including ovarian, endometrial, and cervical cancer, is increasingly recognized.
• These therapies generally present a tolerable side effect profile.

Purpose of the Study:

• To review the activity of PD-1 and PD-L1 inhibitors in gynecologic cancers.
• To highlight the significance of mismatch repair deficiency (dMMR) as a predictive biomarker.
• To recommend further biomarker investigation and clinical application.

Main Methods:

• Review of existing clinical trial data and scientific literature.
• Analysis of response rates and safety profiles of PD-1/PD-L1 inhibitors in gynecologic cancers.
• Evaluation of biomarker data, particularly mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-H).

Main Results:

• PD-1 and PD-L1 inhibitors demonstrate activity across ovarian, endometrial, and cervical cancers.
• The highest response rates were observed in mismatch repair-deficient (dMMR) endometrial cancers.
• Mismatch repair deficiency (dMMR) and high microsatellite instability (MSI-H) are key predictive biomarkers.

Conclusions:

• PD-1 and PD-L1 inhibitors are a viable treatment option for patients with advanced gynecologic malignancies.
• Tumor testing for mismatch repair deficiency (dMMR) or high microsatellite instability (MSI-H) should be considered for all women with progressive disease.
• Pembrolizumab, in particular, shows significant promise in dMMR/MSI-H gynecologic cancers, warranting its consideration as a treatment option.